Cargando…
Pandemic Preparedness Against Influenza: DNA Vaccine for Rapid Relief
The 2009 “swine flu” pandemic outbreak demonstrated the limiting capacity for egg-based vaccines with respect to global vaccine supply within a timely fashion. New vaccine platforms that efficiently can quench pandemic influenza emergences are urgently needed. Since 2009, there has been a profound d...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8531196/ https://www.ncbi.nlm.nih.gov/pubmed/34691056 http://dx.doi.org/10.3389/fimmu.2021.747032 |
_version_ | 1784586799924903936 |
---|---|
author | Andersen, Tor Kristian Bodin, Johanna Oftung, Fredrik Bogen, Bjarne Mjaaland, Siri Grødeland, Gunnveig |
author_facet | Andersen, Tor Kristian Bodin, Johanna Oftung, Fredrik Bogen, Bjarne Mjaaland, Siri Grødeland, Gunnveig |
author_sort | Andersen, Tor Kristian |
collection | PubMed |
description | The 2009 “swine flu” pandemic outbreak demonstrated the limiting capacity for egg-based vaccines with respect to global vaccine supply within a timely fashion. New vaccine platforms that efficiently can quench pandemic influenza emergences are urgently needed. Since 2009, there has been a profound development of new vaccine platform technologies with respect to prophylactic use in the population, including DNA vaccines. These vaccines are particularly well suited for global pandemic responses as the DNA format is temperature stable and the production process is cheap and rapid. Here, we show that by targeting influenza antigens directly to antigen presenting cells (APC), DNA vaccine efficacy equals that of conventional technologies. A single dose of naked DNA encoding hemagglutinin (HA) from influenza/A/California/2009 (H1N1), linked to a targeting moiety directing the vaccine to major histocompatibility complex class II (MHCII) molecules, raised similar humoral immune responses as the adjuvanted split virion vaccine Pandemrix, widely administered in the 2009 pandemic. Both vaccine formats rapidly induced serum antibodies that could protect mice already 8 days after a single immunization, in contrast to the slower kinetics of a seasonal trivalent inactivated influenza vaccine (TIV). Importantly, the DNA vaccine also elicited cytotoxic T-cell responses that reduced morbidity after vaccination, in contrast to very limited T-cell responses seen after immunization with Pandemrix and TIV. These data demonstrate that DNA vaccines has the potential as a single dose platform vaccine, with rapid protective effects without the need for adjuvant, and confirms the relevance of naked DNA vaccines as candidates for pandemic preparedness. |
format | Online Article Text |
id | pubmed-8531196 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-85311962021-10-23 Pandemic Preparedness Against Influenza: DNA Vaccine for Rapid Relief Andersen, Tor Kristian Bodin, Johanna Oftung, Fredrik Bogen, Bjarne Mjaaland, Siri Grødeland, Gunnveig Front Immunol Immunology The 2009 “swine flu” pandemic outbreak demonstrated the limiting capacity for egg-based vaccines with respect to global vaccine supply within a timely fashion. New vaccine platforms that efficiently can quench pandemic influenza emergences are urgently needed. Since 2009, there has been a profound development of new vaccine platform technologies with respect to prophylactic use in the population, including DNA vaccines. These vaccines are particularly well suited for global pandemic responses as the DNA format is temperature stable and the production process is cheap and rapid. Here, we show that by targeting influenza antigens directly to antigen presenting cells (APC), DNA vaccine efficacy equals that of conventional technologies. A single dose of naked DNA encoding hemagglutinin (HA) from influenza/A/California/2009 (H1N1), linked to a targeting moiety directing the vaccine to major histocompatibility complex class II (MHCII) molecules, raised similar humoral immune responses as the adjuvanted split virion vaccine Pandemrix, widely administered in the 2009 pandemic. Both vaccine formats rapidly induced serum antibodies that could protect mice already 8 days after a single immunization, in contrast to the slower kinetics of a seasonal trivalent inactivated influenza vaccine (TIV). Importantly, the DNA vaccine also elicited cytotoxic T-cell responses that reduced morbidity after vaccination, in contrast to very limited T-cell responses seen after immunization with Pandemrix and TIV. These data demonstrate that DNA vaccines has the potential as a single dose platform vaccine, with rapid protective effects without the need for adjuvant, and confirms the relevance of naked DNA vaccines as candidates for pandemic preparedness. Frontiers Media S.A. 2021-10-08 /pmc/articles/PMC8531196/ /pubmed/34691056 http://dx.doi.org/10.3389/fimmu.2021.747032 Text en Copyright © 2021 Andersen, Bodin, Oftung, Bogen, Mjaaland and Grødeland https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Immunology Andersen, Tor Kristian Bodin, Johanna Oftung, Fredrik Bogen, Bjarne Mjaaland, Siri Grødeland, Gunnveig Pandemic Preparedness Against Influenza: DNA Vaccine for Rapid Relief |
title | Pandemic Preparedness Against Influenza: DNA Vaccine for Rapid Relief |
title_full | Pandemic Preparedness Against Influenza: DNA Vaccine for Rapid Relief |
title_fullStr | Pandemic Preparedness Against Influenza: DNA Vaccine for Rapid Relief |
title_full_unstemmed | Pandemic Preparedness Against Influenza: DNA Vaccine for Rapid Relief |
title_short | Pandemic Preparedness Against Influenza: DNA Vaccine for Rapid Relief |
title_sort | pandemic preparedness against influenza: dna vaccine for rapid relief |
topic | Immunology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8531196/ https://www.ncbi.nlm.nih.gov/pubmed/34691056 http://dx.doi.org/10.3389/fimmu.2021.747032 |
work_keys_str_mv | AT andersentorkristian pandemicpreparednessagainstinfluenzadnavaccineforrapidrelief AT bodinjohanna pandemicpreparednessagainstinfluenzadnavaccineforrapidrelief AT oftungfredrik pandemicpreparednessagainstinfluenzadnavaccineforrapidrelief AT bogenbjarne pandemicpreparednessagainstinfluenzadnavaccineforrapidrelief AT mjaalandsiri pandemicpreparednessagainstinfluenzadnavaccineforrapidrelief AT grødelandgunnveig pandemicpreparednessagainstinfluenzadnavaccineforrapidrelief |